COVID

Ifenprodil, 20 mg TID Ifenprodil, 40 mg TID

NP-120 (Ifenprodil)

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

Not hospitalized, no limitations on activities
Not hospitalized, limitation on activities
Hospitalized, not requiring supplemental oxygen
Hospitalized, requiring supplemental oxygen
Hospitalized, on non-invasive ventilation or high flow oxygen devices
Hospitalized, on invasive mechanical ventilation or ECMO
Death

Algernon Pharmaceuticals

Novotech (Australia)

All participants to receive study intervention.

Retinitis Pigmentosa

After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).

NAC effervescent tablets

Wilmer Eye Institute at Johns Hopkins University

FIGHT-RP 1 Extension Study

A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa

Blood pressure in mmHg will be used in assessing tolerability of N-Acetylcysteine.

Participants will be assessed for the occurrence of any drug-related symptoms which includes nausea, stomach upset, diarrhea, heartburn, constipation, and vomiting. Based on the number and severity of the symptoms, the physician would conclude whether the patient is tolerating the medication or not.

Medication diary provided to participants will be reviewed to see if participants are taking the medication within the designated time frame.

Medication diary provided to participants will be reviewed to see if participants are taking the medication twice a day

Scoring is determined by the number of letters gained or lost per month using Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score and visual acuity score together with an overall score range of 0 to 20/20 where 0 is the worst vision and 20/20 is the best.

Microperimetry (MAIA) is used to test whether there is an increase or decrease in sensitivity (dB) in the retina after initiation of N-Acetylcysteine

This will be assessed by spectral domain optical coherence tomography (SD-OCT) after initiation of N-Acetylcysteine.

This will be calculated from the proportions of reduced glutathione and oxidized glutathione in the aqueous.

Johns Hopkins University

Interstitial Pneumonia

London Health Science Centre

The Clinical Course of Interstitial Pneumonia With Autoimmune Features

The Clinical Course of Interstitial Pneumonia With Autoimmune Features: an Observational, Prospective Cohort Study

Survival rate since the time of diagnosis

Incidence of a new diagnosis of autoimmune disease during the 3-year clinical course

Time to either: decline of FVC >10% pred; decline of 6-min walk distance >50 m; hospitalization for respiratory causes; lung transplant assessment; or death.

Incidence of acute exacerbations since the time of diagnosis

Lawson Health Research Institute

Tablet Tadalafil 20 mg every alternate day

Lung Diseases, Interstitial

Tab. Tadalafil 20 mg every other day for 6 months

Tadalafil

Shape , size, color and odor matched Tab. of inert material every other day for 6 months

Placebo

SGPGIMS

A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

To assess the change in FVC (expressed as a percentage of the predicted value) from baseline values at the end of 6 months

To assess the improvement in dyspnoea (as measured by Mehler dyspnoea index) at the end of 6 month

To assess improvement in 6 min walk test at the end of 6 months

To assess the change in DLCO from baseline values at the end of 6 months

To assess the change in total lung capacity from baseline values at the end of 6 months

To assess the change in the disability index of the Health Assessment Questionnaire (S HAQ) at 6 months from baseline

To assess the change in the Medical Outcomes Study 36-item Short-Form General Health Survey (SF-36) from baseline to end of 6 months

idiopathic pulmonary fibrosis/edema

Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease

FIGHT-RP 1 Extension Study

The Clinical Course of Interstitial Pneumonia With Autoimmune Features

A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma

科学に裏打ちされた最も完全な薬草データベース